Skip to main content

Structural Bioinformatics Licenses Database to De Novo

NEW YORK, Nov 21 – Structural Bioinformatics of San Diego said Tuesday it had licensed its SBdBase database of 3-dimensional protein structures to De Novo Pharmaceuticals.

Under the terms of the deal, De Novo will have access to multiple therapeutic target classes, Structural Bioinformatics said in a statement.

Financial terms were not disclosed.

" The combination of SBI's proprietary protein structures with De Novo's powerful proprietary drug design algorithms extends our design platform from experimentally determined protein structures to the broader world of sequence-based information,” David Bailey, De Novo's CEO, said.

“The agreement with SBI will allow De Novo to expand its drug design partnerships with early-stage genomics targets," he said. 

De Novo of Cambridge, UK, uses proprietary computational software for drug design to create lead molecules as candidates for drug development.

De Novo has collaborated with British Biotechnology and Aventis Pharma.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.